美国FDA生物制品紫皮书数据库（U.S. FDA Purple Book: Database of Licensed Biological Products）- 药物在线

商品名	申请号	产品号	BLA类型	非专利名称	剂型	给药途径	规格/剂量	产品形式	批准日期	申请人	市场状态	许可证状态	参考产品非专利名称	参考产品专利名称
PENMENVY	125819	001	351(a)	Meningococcal Groups A, B, C, W and Y Vaccine	Injection	Intramuscular	25UG/0.5ML	Single-Dose Vial	2025/02/14	GlaxoSmithKline Biologicals	Rx	Licensed
VIMKUNYA	125820	001	351(a)	Chikungunya Vaccine, Recombinant	Injection	Intramuscular	40UG/0.8ML	Pre-Filled Syringe	2025/02/14	Bavarian Nordic A/S	Rx	Licensed
Avtozma	761420	001	351(k) Interchangeable	tocilizumab-anoh	Injection	Intravenous	80MG/4ML (20MG/ML)	Single-Dose Vial	2025/01/24	CELLTRION, Inc.	Rx	Licensed	tocilizumab	Actemra
Avtozma	761420	002	351(k) Interchangeable	tocilizumab-anoh	Injection	Intravenous	200MG/10ML (20MG/ML)	Single-Dose Vial	2025/01/24	CELLTRION, Inc.	Rx	Licensed	tocilizumab	Actemra
Avtozma	761420	003	351(k) Interchangeable	tocilizumab-anoh	Injection	Intravenous	400MG/20ML (20MG/ML)	Single-Dose Vial	2025/01/24	CELLTRION, Inc.	Rx	Licensed	tocilizumab	Actemra
Avtozma	761420	004	351(k) Interchangeable	tocilizumab-anoh	Injection	Subcutaneous	162MG/0.9ML	Pre-Filled Syringe	2025/01/24	CELLTRION, Inc.	Rx	Licensed	tocilizumab	Actemra
Avtozma	761420	005	351(k) Biosimilar	tocilizumab-anoh	Injection	Subcutaneous	162MG/0.9ML	Autoinjector	2025/01/24	CELLTRION, Inc.	Rx	Licensed	tocilizumab	Actemra
Datroway	761394	001	351(a)	datopotamab deruxtecan-dlnk	Injection	Intravenous	100MG	Single-Dose Vial	2025/01/17	Daiichi Sankyo, Inc	Rx	Licensed
Omvoh	761279	003	351(a)	mirikizumab-mrkz	Injection	Subcutaneous	100MG/ML	Autoinjector	2025/01/15	Eli Lilly and Company	Rx	Licensed
Omvoh	761279	004	351(a)	mirikizumab-mrkz	Injection	Subcutaneous	200MG/2ML (100MG/ML)	Autoinjector	2025/01/15	Eli Lilly and Company	Rx	Licensed
Omvoh	761279	005	351(a)	mirikizumab-mrkz	Injection	Subcutaneous	200MG/2ML (100MG/ML)	Pre-Filled Syringe	2025/01/15	Eli Lilly and Company	Rx	Licensed
Opdivo Qvantig	761381	001	351(a)	nivolumab and hyaluronidase-nvhy	Injection	Subcutaneous	600MG/5ML;10,000 UNITS/5ML (120MG/2,000UNITS/ML)	Single-Dose Vial	2024/12/27	Bristol-Myers Squibb Company	Rx	Licensed
Wezlana	761285	004	351(k) Biosimilar	ustekinumab-auub	Injection	Subcutaneous	45MG/0.5ML	Autoinjector	2024/12/26	Amgen Inc.	Rx	Licensed	ustekinumab	Stelara
Wezlana	761285	005	351(k) Biosimilar	ustekinumab-auub	Injection	Subcutaneous	90MG/ML	Autoinjector	2024/12/26	Amgen Inc.	Rx	Licensed	ustekinumab	Stelara
Alhemo	761315	002	351(a)	concizumab-mtci	Injection	Subcutaneous	150MG/1.5ML (100MG/ML)	Autoinjector	2024/12/20	Novo Nordisk Inc.	Rx	Licensed
Pyzchiva	761373	003	351(k) Biosimilar	ustekinumab-ttwe	Injection	Subcutaneous	45MG/0.5ML	Single-Dose Vial	2024/12/20	Samsung Bioepis Co., Ltd.	Rx	Licensed	ustekinumab	Stelara
Alhemo	761315	001	351(a)	concizumab-mtci	Injection	Subcutaneous	60MG/1.5ML (40MG/ML)	Autoinjector	2024/12/20	Novo Nordisk Inc.	Rx	Licensed
Alhemo	761315	003	351(a)	concizumab-mtci	Injection	Subcutaneous	300MG/3ML (100MG/ML)	Autoinjector	2024/12/20	Novo Nordisk Inc.	Rx	Licensed
symvess	125812	001	351(a)	acellular tissue engineered vessel-tyod	Implant	Implantation	6 MM INTERNAL DIAMETER,~42 CM LENGTH	Tray & Lid	2024/12/19	Humacyte Global Inc.	Rx	Licensed
ryoncil	125706	001	351(a)	remestemcel-L-rknd	Suspension	Intravenous	6.68X10^CELL/ML	Single-Dose Vial	2024/12/18	Mesoblast, Inc.	Rx	Licensed

药品商品名或专利药名Proprietary (Brand) Name
药品通用名或非专利名称Nonproprietary (Proper) Name
药品申请号BLA Number
产品号Product Number
剂型Dosage Form
给药途径Route of Administration
产品形式Product Presentation
药品规格或剂量Strength
药品注册申请人Applicant
参考产品非专利名称Reference Product Proper Name
参考产品专利名称Reference Product Proprietary Name
BLA类型BLA Type
药品的市场状态Marketing Status
许可证号License Number
许可证状态Licensure
产品批准日期Approval Date	-